ArticleAlzheimer's research & therapy2025

Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system].

Xiaoxuan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.